Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Neurosurgical Navigation Robot Combines AI and Machine Vision to Streamline Procedures

By HospiMedica International staff writers
Posted on 09 Aug 2022

Amidst the increasing demand for minimally invasive surgery, neuro-navigation has become standard in neurosurgery worldwide. More...

Currently, most navigation systems use a “vision-based optical tracking system” during the registration step. Image-guided surgery is used for intra-operative navigation assistance for neurosurgical problems. However, such solutions require some specific space to be maintained between the device cameras, the probe, and the microscope in order to eliminate obstruction. Now, a new autopilot neurosurgical navigation robot that combines robotic technology, artificial intelligence (AI) and machine vision could assist in surgical procedures such as biopsy, deep brain stimulation (DBS), stereoelectroencephalography (SEEG), endoscopic surgery, and external ventricular drainage (EVD).

NaoTrac, a CE-certified neurosurgical navigation robot from Brain Navi Biotechnology (Hsinchu, Taiwan), uses the company’s proprietary Surface Mapping Auto-Registration Technology (SMART) technology that merges machine vision, robotics, and AI to streamline surgical procedures with real-time imaging and minimally invasive outcomes. NaoTrac can be used for surgeries like endoscopic brain surgery, cell implantation, and other operations. NaoTrac’s unique autonomous procedure enables surgical navigation with non-contact registration, pre-operative planning preparation, and choosing the surgery pathway with 3D vision for precise anatomical location.

NaoTrac has achieved approval from Taiwan's Food and Drug Administration (TFDA) and the company is now planning a submission to the FDA (U.S. Food and Drug Administration) for clearance by the end of 2022. Human trials of NaoTrac performed with EVD placement have shown that the results were good to perfect with high precision.

"The results of this report show that the average time spent on the patient registration was 1423.8 seconds. The mean target deviation was 1.68mm, and the mean angular deviation was 1.99 degrees, all within the accepted tolerance for minimal tissue damage," said Dr. Tsung-Lang, Chiu. "NaoTrac has several advantages besides the high precision, like a non-invasive, non-contact patient registration process with a fast and accurate procedure, the system provides precise navigation to the surgical target. It's also user-friendly, and has many other benefits."

Related Links:
Brain Navi Biotechnology 


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.